Translational Package

The Translational Package is designed for oncology programs entering late preclinical development, IND-enabling stages, or early clinical trials.

It provides robust functional validation on patient-derived tumor models, helping you refine patient selection, optimize combinations, and support regulatory and investor discussions with clinically relevant data.

Even promising assets can fail due to:

• Lack of patient stratification strategy
• Insufficient understanding of responder subpopulations
• Weak translational linkage between preclinical models and clinical setting

Our Translational Package reduces this risk by generating human tumor–based functional evidence before or alongside clinical development.

1) Cohort Expansion & Validation

Building upon Discovery data, we expand testing to:

• Larger patient-derived tumor cohorts
• Multiple tumor subtypes within an indication
• Defined molecular backgrounds (if required)

This allows:

• Confirmation of activity consistency
• Identification of high-response subgroups
• Quantification of inter-patient variability

2) Responder vs Non-Responder Stratification

We functionally classify tumor samples based on treatment response and generate:

• Responder enrichment patterns
• Sensitivity distribution across the cohort
• Combination performance ranking
• Functional synergy confirmation

This provides a foundation for:

• Clinical inclusion criteria refinement
• Companion diagnostic strategy exploration
• Target population definition

3) Advanced Mechanistic Integration

Optional modules to deepen translational value:

Molecular profiling

• RT-PCR / qPCR panels
• Gene expression correlations
• Target pathway modulation

Protein & pathway analysis

• Western blot validation
• Flow cytometry phenotyping
• Immunocytochemistry
• Apoptosis / proliferation signaling

Functional biomarkers

• Ki-67
• TUNEL
• ELISA nucleosome release
• Viability/apoptosis quantification

Goal: Link functional efficacy to biological rationale.

4) Combination Optimization

For assets intended for combination therapy:

• Standard of care + investigational agent
• Investigational + investigational
• Dose ratio optimization
• Functional synergy mapping

This strengthens:

• Phase I/II combination strategy
• Clinical protocol design
• Competitive positioning

You receive a comprehensive translational report including:

• Cohort-level efficacy analysis
• Response distribution plots
• Responder enrichment patterns
• Combination ranking and synergy assessment
• Correlation between functional response and biological markers

The Translational Package supports:

• Phase I/II study design
• Patient stratification strategy
• Go/no-go milestone decisions
• Companion diagnostic exploration
• Competitive differentiation
• Licensing or co-development discussions

• Patient-derived primary tumor cultures
• Preservation of tumor heterogeneity
• Standardized, clinically oriented functional assay conditions
• Faster and more agile than PDX
• Human-based evidence reducing translational gap

• Biotechs preparing for IND submission
• Pharma optimizing early clinical trials
• Companies developing precision oncology strategies
• Programs seeking stronger human data before large capital deployment

From Preclinical Promise to Clinical Strategy

The Translational Package transforms early efficacy signals into clinically meaningful evidence, helping you move forward with confidence.